Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Comparison Between Anterior Segment Optical Coherence Tomography and Ultrasound Bio Microscopy Parameters in Glaucoma Assessment

NCT05730478 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2023-03-01
Last updated
2024-11-15

Condition(s) studied

Glaucoma Eye

Investigational drug(s) / intervention(s)

ASOCT&UBMGlaucoma therapyGlaucoma therapy

ASOCT&UBM: glaucoma assesment by ASOCT \&UBM

Glaucoma therapy: ASOCT and UBM parameters Comparison

Glaucoma therapy: Comparison

Study summary

Study aiming to compare between anterior segment Optical Coherence Tomography and Ultrasound BioMicroscopy In Glaucoma aSSESMENT

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with open and angle closure glaucoma. Male and female patients were included. Patient age: more than18 years old Exclusion Criteria: Previous glaucoma surgery. Previous cataract surgery. Media opacity. Associated ocular or intra ocular inflammation. Associated corneal pathology.

Primary outcome measure(s)

  • comparison between Anterior Segment Optical Coherence Tomography And ltrasound Biomicroscopy Parameters In Glaucoma Assesment — 1 year
    . UBM provides biometric information of anterior segment structures, such as anterior chamber (AC) depth, anterior chamber angle (ACA), and iris thickness. UBM provides more detailed information compared to slit-lamp, gonioscopy or B-scan examinations for diagnosis and follow-up of PAC eyes. It can be used to study the causes of secondary glaucoma. Precise quantitative evaluation of the anterior chamber angle structures can help in diagnosis and management of various pathologies related to glaucoma . anterior segment-optical coherence tomography (AS-OCT) has developed rapidly. With a higher imaging resolution than UBM, AS-OCT makes it easier for the operator and software to identify ACA structures. such as: the scleral spur (SS), iris surface, Schwalbe's line, even trabecular meshwork , and Schlemm's canal. This provides more precise analysis of the angle opening distance from the SS, ACA, trabecular iris angle , and trabecular iris space area

Trial sites (1)

FacilityCityRegionStatus
Marwa Adel, Sohag Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05730478 on ClinicalTrials.gov ↗ ← All trials in Egypt